These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7499491)

  • 1. Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody.
    Lee SC; Kress Y; Dickson DW; Casadevall A
    J Neuroimmunol; 1995 Oct; 62(1):43-52. PubMed ID: 7499491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins.
    Mukherjee S; Feldmesser M; Casadevall A
    J Infect Dis; 1996 May; 173(5):1222-31. PubMed ID: 8627076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal activity of a human antiglucuronoxylomannan antibody.
    Zhong Z; Pirofski LA
    Clin Diagn Lab Immunol; 1998 Jan; 5(1):58-64. PubMed ID: 9455881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.
    Mukherjee S; Lee SC; Casadevall A
    Infect Immun; 1995 Feb; 63(2):573-9. PubMed ID: 7822024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
    Martinez LR; Moussai D; Casadevall A
    Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
    Cleare W; Cherniak R; Casadevall A
    Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phagocytosis of nonopsonized Cryptococcus neoformans by swine microglia involves CD14 receptors.
    Lipovsky MM; Gekker G; Anderson WR; Molitor TW; Peterson PK; Hoepelman AI
    Clin Immunol Immunopathol; 1997 Aug; 84(2):208-11. PubMed ID: 9245554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
    Todaro-Luck F; White EH; Reiss E; Cherniak R
    Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.
    Rachini A; Pietrella D; Lupo P; Torosantucci A; Chiani P; Bromuro C; Proietti C; Bistoni F; Cassone A; Vecchiarelli A
    Infect Immun; 2007 Nov; 75(11):5085-94. PubMed ID: 17606600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
    Netski D; Kozel TR
    Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
    Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody mediated capsular reactions (Quellung) in Cryptococcus neoformans.
    Mukherjee J; Cleare W; Casadevall A
    J Immunol Methods; 1995 Jul; 184(1):139-43. PubMed ID: 7622865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies.
    Cleare W; Mukherjee S; Spitzer ED; Casadevall A
    Clin Diagn Lab Immunol; 1994 Nov; 1(6):737-40. PubMed ID: 8556529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
    Mukherjee J; Zuckier LS; Scharff MD; Casadevall A
    Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptococcus neoformans induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta in human microglia: role of specific antibody and soluble capsular polysaccharide.
    Goldman D; Song X; Kitai R; Casadevall A; Zhao ML; Lee SC
    Infect Immun; 2001 Mar; 69(3):1808-15. PubMed ID: 11179358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
    Duro RM; Netski D; Thorkildson P; Kozel TR
    Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
    Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
    Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.
    Mukherjee J; Scharff MD; Casadevall A
    Infect Immun; 1995 Sep; 63(9):3353-9. PubMed ID: 7642262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
    Mukherjee J; Kozel TR; Casadevall A
    J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells.
    Vecchiarelli A; Pietrella D; Bistoni F; Kozel TR; Casadevall A
    Immunology; 2002 Jun; 106(2):267-72. PubMed ID: 12047756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.